首页> 外文期刊>Modern Pathology >PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas
【24h】

PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas

机译:低恶性潜在卵巢肿瘤和低级卵巢浆液癌中的PAX2表达

获取原文
           

摘要

Ovarian tumors of low malignant potential and low-grade ovarian serous carcinomas are thought to represent different stages on a tumorigenic continuum and to develop along pathways distinct from high-grade ovarian serous carcinoma. We performed gene expression profiling on three normal human ovarian surface epithelia samples, and 10 low-grade and 10 high-grade ovarian serous carcinomas. Analysis of gene expression profiles of these samples has identified 80 genes upregulated and 232 genes downregulated in low-grade ovarian serous carcinomas. PAX2 was found to be one of the most upregulated genes in low-grade ovarian serous carcinoma. The upregulation of PAX2 was validated by real-time quantitative RT-PCR, western blot and immunohistochemical analyses. Real-time RT-PCR showed a statistically significant difference in PAX2 mRNA expression (expressed as fold change in comparison to normal human ovarian surface epithelia) among ovarian tumors of low malignant potential (1837.38, N=8), low-grade (183.12, N=17), and high-grade (3.72, N=23) carcinoma samples (P=0.015). Western blot analysis revealed strong PAX2 expression in ovarian tumors of low malignant potential (67%, N=3) and low-grade carcinoma samples (50%, N=10) but no PAX2 protein expression in high-grade carcinomas (0%, N=10). Using immunohistochemistry, tumors of low malignant potential (59%, N=17) and low-grade carcinoma (63%, N=16) samples expressed significantly stronger nuclear staining than high-grade ovarian carcinoma samples (9.1%, N=263). Furthermore, consistent with earlier immunohistochemical findings, PAX2 expression was expressed in the epithelial cells of fallopian tubes but not in normal ovarian surface epithelial cells. Our findings further support the two-tiered hypothesis that tumors of low malignant potential and low-grade ovarian serous carcinoma are on a continuum and are distinct from high-grade ovarian carcinomas. In addition, the absence of PAX2 expression in normal ovarian epithelia but expression in fallopian tube fimbria and ciliated epithelial inclusions would suggest the potential development of tumors of low malignant potential and of low-grade ovarian serous carcinomas from secondary Müllerian structures.
机译:低恶性潜力和低级卵巢浆液癌的卵巢肿瘤被认为是在肿瘤内连续体上的不同阶段,并且沿着与高级卵巢浆液癌不同的途径发展。我们对三个正常人体卵巢表面上皮样品进行了基因表达分析,以及10个低级和10个高级卵巢浆液癌。这些样品的基因表达谱分析已经确定了80个基因上调和232个基因在低级卵巢浆液癌中下调。发现PAX2是低级卵巢浆液癌中最具上调的基因之一。通过实时定量RT-PCR,Western印迹和免疫组织化学分析验证PAX2的上调。实时RT-PCR在低恶性潜力的卵巢肿瘤(1837.38,N = 8),低等级(183.12,183.12, n = 17),高级(3.72,n = 23)癌样品(P = 0.015)。 Western印迹分析显示出低恶性电位的卵巢肿瘤(67 %,n = 3)和低级癌样品(50℃,n = 10)但在高等癌中没有pAX2蛋白表达(0 %,n = 10)。使用免疫组织化学,低恶性电位(59 %,N = 17)和低级癌(63 %,n = 16)样品的肿瘤表达明显较强的核染色,而不是高级卵巢癌样品(9.1 %,n = 263)。此外,与早期免疫组织化学发现一致,PAX2表达在输卵管的上皮细胞中表达,但不在正常的卵巢表面上皮细胞中。我们的研究结果进一步支持双层假设,即低恶性潜力和低级卵巢浆液癌的肿瘤都在连续核,并且与高级卵巢癌不同。此外,在正常卵巢上皮细胞中没有PAX2表达,但在输卵管症中的表达和纤维的上皮夹杂物都会表明来自次级Müllerian结构的低恶性潜力和低级卵巢浆液癌的潜在发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号